Monthly Archives: March 2020

The Balancing Act: Taking A Systematic Approach To Hard Decisions In Times Of Rapid Change
March 30, 2020

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  If CEOs have empowered their teams effectively, they have three roles during times of rapid change: Motivator in chief

Leave a comment

Strategic Planning In Biotech During A Pandemic Crisis
March 26, 2020

In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business disruptions are significant and overwhelming, the primary efforts focused on both safety

Leave a comment

Recipe For Managing Data Disclosure Successfully With Academic Partners: A Public Gene Therapy Company Perspective
March 24, 2020

This blog post was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting

Leave a comment

Coming Together While Staying Apart
March 23, 2020

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. I have never participated in trench warfare and I am sure it was pretty grim for those who lived and

Leave a comment

Core (Values) Workout
March 5, 2020

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done:

Leave a comment

BioPharma M&A Drives More Efficient Resource Allocation
March 2, 2020

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets

Leave a comment